ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $26,426 | -34.7% | 659 | -24.5% | 0.00% | -33.3% |
Q4 2022 | $40,446 | +12.4% | 873 | 0.0% | 0.01% | 0.0% |
Q3 2022 | $36,000 | -30.8% | 873 | 0.0% | 0.01% | -25.0% |
Q2 2022 | $52,000 | -5.5% | 873 | +15.6% | 0.01% | +14.3% |
Q1 2022 | $55,000 | -12.7% | 755 | 0.0% | 0.01% | -12.5% |
Q4 2021 | $63,000 | -7.4% | 755 | 0.0% | 0.01% | -11.1% |
Q3 2021 | $68,000 | -5.6% | 755 | 0.0% | 0.01% | -10.0% |
Q2 2021 | $72,000 | -24.2% | 755 | -9.0% | 0.01% | -28.6% |
Q1 2021 | $95,000 | -24.0% | 830 | -8.1% | 0.01% | -30.0% |
Q4 2020 | $125,000 | +101.6% | 903 | +20.4% | 0.02% | +66.7% |
Q3 2020 | $62,000 | +77.1% | 750 | +69.7% | 0.01% | +71.4% |
Q2 2020 | $35,000 | +75.0% | 442 | 0.0% | 0.01% | +40.0% |
Q1 2020 | $20,000 | – | 442 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 441,159 | $39,788,000 | 2.62% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,100 | $9,286,000 | 2.24% |
Rock Springs Capital Management LP | 801,109 | $72,252,000 | 1.52% |
Avidity Partners Management LP | 455,000 | $41,036,000 | 0.91% |
Motley Fool Asset Management LLC | 134,357 | $12,118,000 | 0.79% |
FEDERATED HERMES, INC. | 3,987,032 | $359,590,000 | 0.68% |
EMERALD ADVISERS, LLC | 196,124 | $17,688,000 | 0.64% |
Ergoteles LLC | 128,100 | $11,553,000 | 0.42% |
Tekla Capital Management LLC | 140,726 | $12,692,000 | 0.41% |
Beck Bode, LLC | 14,990 | $1,352,000 | 0.38% |